Bicara Therapeutics' stock surged 5.55% during pre-market trading on Monday, following the release of its fourth quarter and full year 2025 financial results and business update.
The company was scheduled to report its quarterly earnings before market open, as indicated in the weekly earnings calendar. The actual earnings release, which includes both financial results and a business update, is the likely catalyst for the significant pre-market movement.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.